SCHEMBL4258671

SCHEMBL4258671

COC(=O)c1cc(Cl)n2nccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.54
NOTUM Q6P988 2/20 0.40
F2 P00734 1/20 0.40
PLAU P00749 1/20 0.40
KLKB1 P03952 1/20 0.40
ELANE P08246 1/20 0.40
PIM1 P11309 2/20 0.39
PIM3 Q86V86 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
AURKA O14965 1/20 0.39
JAK2 O60674 1/20 0.39
NTRK1 P04629 1/20 0.39
RET P07949 1/20 0.39
FGFR1 P11362 1/20 0.39
PRKACA P17612 1/20 0.39
LTK P29376 1/20 0.39
KDR P35968 1/20 0.39
MAP2K2 P36507 1/20 0.39
FLT3 P36888 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL897271 0.86 PDE4A (0.49) PDE10ANOTUMALDH1A1KDM4EHPGD
SCHEMBL8253106 0.84 LCK (0.42) PDE10AF2PLAUKLKB1ELANE
SCHEMBL4260174 0.83 PIM1 (0.40) PDE10APIM1PIM3PLK3PIM2
SCHEMBL351584 0.83 KDM4E (0.46) PDE10APIM1PIM3PLK3PIM2
SCHEMBL8174140 0.83 PDE10A (0.59) PDE10APIM1PIM3PLK3PIM2
SCHEMBL4215549 0.82 PIM1 (0.45) PDE10AF2PLAUKLKB1ELANE
SCHEMBL8180903 0.82 KDR (0.41) PDE10APIM1PIM3PLK3PIM2
SCHEMBL10164479 0.82 LCK (0.40) PDE10AF2PLAUKLKB1ELANE
Hydrochloric Acid SCHEMBL4262712 0.81 KDR (0.40) PDE10APIM1PIM3PLK3PIM2
SCHEMBL10165296 0.81 AURKA (0.46) F2PLAUKLKB1ELANEPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102211-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS Alantos Pharmaceuticals Holding, Inc. (US) 2009-09-23 EP disclosed
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors NOLTE BERT 2008-07-24 US disclosed
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors NOLTE BERT 2008-07-24 US disclosed
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors NOLTE BERT 2008-07-24 US disclosed
WO-2008063671-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed
WO-2008063671-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176870-A1 Heterobicyclic metalloprotease inhibitors ADAM17, ADAM8, ADAM10 PDE10A 4145/4885NOTUM 322/4885F2 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.